Related Experiment Video

Updated: Apr 23, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Emerging drugs targeting PD-1 and PD-L1: reality or hope?

Francesca Casaluce1, Assunta Sgambato, Paola Claudia Sacco

  • 1Second University of Naples, Department of Clinical and Experimental Medicine , Naples , Italy.

Expert Opinion on Emerging Drugs
|September 26, 2014
PubMed
Abstract

Insights

Novel immunotherapies targeting immune checkpoints show promise for lung cancer. Further clinical studies are needed to confirm the efficacy of these programmed cell death protein 1 (PD-1) pathway inhibitors.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tumors utilize immune checkpoint pathways for immune evasion.
  • Understanding these mechanisms drives the development of novel immunotherapies.
  • These therapies aim to restore the patient's immune system against cancer cells.

Purpose of the Study:

  • To review the immunomodulatory environment in non-small cell lung cancer (NSCLC).
  • To focus on immune-checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) pathway.
  • To summarize current clinical data for these agents in lung cancer.

Main Methods:

  • Review of clinical development of anti-PD-1 and anti-PD-L1 agents.
  • Analysis of preliminary efficacy data for monotherapy and combination treatments.
  • Synthesis of information on the immunomodulatory landscape in NSCLC.

Main Results:

  • Agents targeting the PD-1 pathway are in active clinical development for lung cancer.
  • Preliminary data suggest promising efficacy for these agents.
  • Both monotherapy and combination with chemotherapy are being investigated.

Conclusions:

  • Immune-mediated therapies offer a promising new approach for lung cancer treatment.
  • Evidence is still emerging, requiring further clinical investigation.
  • More data are needed to optimize the clinical impact of these novel therapies.
Keywords:
NSCLCanti-programmed cell death protein agentsanti-programmed death ligand-1 agentsimmune checkpointsnivolumab

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

2.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
96
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148